Obesity and atypical depression symptoms: findings from Mendelian randomization in two European cohorts. by Pistis, G. et al.
Pistis et al. Translational Psychiatry           (2021) 11:96 
https://doi.org/10.1038/s41398-021-01236-7 Translational Psychiatry
ART ICLE Open Ac ce s s
Obesity and atypical depression symptoms:
findings from Mendelian randomization in two
European cohorts
Giorgio Pistis 1, Yuri Milaneschi2, Caroline L. Vandeleur1, Aurélie M. Lasserre 1, Brenda W.J.H. Penninx2,
Femke Lamers2, Dorret I. Boomsma 3, Jouke-Jan Hottenga 3, Pedro Marques-Vidal 4, Peter Vollenweider4,
Gérard Waeber 4, Jean-Michel Aubry5, Martin Preisig1 and Zoltán Kutalik 6,7
Abstract
Studies considering the causal role of body mass index (BMI) for the predisposition of major depressive disorder (MDD)
based on a Mendelian Randomization (MR) approach have shown contradictory results. These inconsistent findings
may be attributable to the heterogeneity of MDD; in fact, several studies have documented associations between BMI
and mainly the atypical subtype of MDD. Using a MR approach, we investigated the potential causal role of obesity in
both the atypical subtype and its five specific symptoms assessed according to the Statistical Manual of Mental
Disorders (DSM), in two large European cohorts, CoLaus|PsyCoLaus (n= 3350, 1461 cases and 1889 controls) and
NESDA|NTR (n= 4139, 1182 cases and 2957 controls). We first tested general obesity measured by BMI and then the
body fat distribution measured by waist-to-hip ratio (WHR). Results suggested that BMI is potentially causally related to
the symptom increase in appetite, for which inverse variance weighted, simple median and weighted median MR
regression estimated slopes were 0.68 (SE= 0.23, p= 0.004), 0.77 (SE= 0.37, p= 0.036), and 1.11 (SE= 0.39, p= 0.004).
No causal effect of BMI or WHR was found on the risk of the atypical subtype or for any of the other atypical
symptoms. Our findings show that higher obesity is likely causal for the specific symptom of increase in appetite in
depressed participants and reiterate the need to study depression at the granular level of its symptoms to further
elucidate potential causal relationships and gain additional insight into its biological underpinnings.
Introduction
Major depressive disorder (MDD) and obesity are major
public health concerns worldwide, which entail an excess
of premature mortality1,2. Studies have repeatedly docu-
mented a strong association between depressive disorders
and obesity3–7, but the mechanisms underlying this
association are still poorly understood8,9. Over the last
years, clinical heterogeneity has represented a challenging
impediment to unraveling the complex biology of MDD
and to the comprehension of its relationship with obe-
sity9. The characterization of MDD subtypes, and the
consequent disentanglement of the heterogeneity of
depression, represented a promising strategy to gain more
insight into biological mechanisms related to MDD8,10.
Indeed, using this approach several studies documented
associations between depression and obesity markers that
were mainly restricted to patients endorsing a symptom
profile that has often been labeled as “atypical”11–17.
According to the fourth edition of the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV)18 spe-
cifier, atypical depression is defined by the presence of
mood reactivity and two of the following: hypersomnia,
leaden paralysis, increase in appetite/weight gain, and
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long-standing pattern of interpersonal rejection sensitiv-
ity. Nevertheless, previous studies applied the label of
“atypical” to subgroups of patients selected according to
different definitions: while some studies19,20 strictly
applied the DSM criteria for the atypical specifier, oth-
ers13,14 used a simplified definition based on few symp-
toms (e.g. increase in appetite, hypersomnia, fatigue), or
used classifications based on data-driven methods21. It is
crucial therefore to identify which of the atypical symp-
toms may constitute a major driver of the associations
with obesity. A recent review22 showed indeed that
obesity-related immuno-metabolic dysregulations map
more consistently to atypical, energy-related symptoms
(e.g. hypersomnia, increase in appetite, leaden paralysis,
and fatigue) rather than the entire classical construct of
atypical depression as coded in the DSM. A multicenter
study of 14 datasets of the Psychiatric Genomics Con-
sortium (PGC) recently assessed participants with MDD
and found a strong positive genetic correlation between
MDD patients with increased appetite or weight and body
mass index (BMI), whereas MDD patients with decreased
appetite or weight revealed an inverse genetic correlation
with BMI9. Another recent study23 found that MDD
patients endorsing weight gain and hypersomnia carried a
higher genetic loading for BMI than those without these
symptoms. The association between obesity and atypical
depressive symptoms could be either causal or attribu-
table to shared etiological factors such as genes. Pro-
spective clinical and epidemiological studies suggested
that an elevated BMI predisposes to atypical-like depres-
sive syndromes24,25 but also the converse11,15. Recently,
the Mendelian Randomization (MR) method was applied
to examine whether the relationship between obesity and
the overall diagnosis of depression is likely to be causal.
MR is a potent tool which uses exposure-associated
genetic variants as instrumental variables to estimate the
causal effect of this exposure on an outcome of interest26.
The association between a genetic variation and an out-
come is generally not susceptible to reverse causation or
confounding that may distort interpretations of conven-
tional observational studies27. Studies using the MR
approach showed evidence for a causal role of depression
on BMI increase28, and revealed conflicting results
regarding the causal role of high BMI in increasing
symptom severity scores or the diagnosis of depression29–35.
In particular, despite the large overlap of included studies,
the two largest genome-wide association study (GWAS)
meta-analyses on depression by Wray et al.34 and Howard
et al.35 suggested causal and non-causal effects of BMI on
depression, respectively. Another recent study using the
MR approach found that higher BMI could be a causal
risk factor for, among other depressive symptoms, chan-
ges in appetite but could not differentiate between the
underlying diametrically opposite symptoms of increase
and decrease in appetite36. Again, these inconsistent
findings are likely to be attributable to the heterogeneity
of depression involving the mixing of the liabilities of
different MDD subtypes together and emphasize the
importance of investigating whether the causal association
between obesity and depression is restricted to specific
symptom profiles. The aims of the present study were to
test a potential causal role of obesity on both the atypical
MDD subtype and its five specific symptoms, assessed
according to the DSM-IV, in two large cohorts. Applying
several kinds of MR methods, we primarily tested the
BMI as a measure of general obesity. In a secondary
analysis, we tested the body fat distribution, measured by
waist-to-hip ratio (WHR).
Materials and methods
The analyses were conducted in two cohort studies, the
CoLaus|PsyCoLaus and the NESDA|NTR cohorts.
Participants
CoLaus|PsyCoLaus
CoLaus|PsyCoLaus19,37 is a prospective cohort study
with a baseline and two follow-up assessments to date
designed to study mental disorders and cardiovascular
risk factors in the community and to determine their
associations. The sample of 6734 participants was ran-
domly selected from the 35- to 75-year-old residents of
the city of Lausanne (Switzerland) from 2003 to 2006
according to the civil register. Full genetic data were only
available for Caucasians. The final sample comprised 3350
participants from 35 to 67 years and for whom combined
genetic and psychiatric data were available. From the final
sample of CoLaus|PsyCoLaus participants, 53.31% were
females, the mean age was 51.8 years (SD 8.63 years) and
the mean year of birth was 1954 (SD 8.60 years). Diag-
nostic information on mental disorders was collected at
baseline using the French version20 of the semi-structured
Diagnostic Interview for Genetic Studies (DIGS)38. Life-
time psychiatric diagnoses were assigned according to the
fourth edition of the DSM-IV (ref. 18). The French
translation of the DIGS revealed excellent inter-rater
(Kappa= 0.93) and fair-to-good test–retest reliability
(Kappa= 0.62) for lifetime diagnoses of MDD20. This
interview, which includes questions on increase in appe-
tite or significant weight gain and hypersomnia, was
completed with additional questions on mood reactivity,
leaden paralysis, and interpersonal rejection sensitivity in
order to elicit all five criteria of the specifier for atypical
depression features according to DSM-IV. The interview
systematically assesses the last and the most severe
depressive episodes. A diagnosis of atypical MDD was
assigned if criteria for atypical features were met
according to the specifier in at least one of the two
described episodes. The DSM-IV criteria for atypical
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MDD include (1) mood reactivity and at least two of the
following four symptoms: (2) increase in appetite or sig-
nificant weight gain, (3) hypersomnia, (4) leaden paralysis,
and (5) interpersonal rejection sensitivity. The DIGS also
collects data on a series of socio-demographic factors
including year of birth and gender, which were controlled
for in all analyses. To avoid potential redundancy with
obesity measures, we only applied the appetite part of the
appetite/weight-gain criterion. Interviewers were required
to be masters-level psychologists, and were trained over a
1- to 2-month period. During data collection, each
interview was reviewed by an experienced senior clinical
psychologist. The control group included participants
who did not meet criteria for MDD, but also not for
bipolar disorder, schizoaffective disorder, or schizo-
phrenia. The Institutional Ethics’ Committee of the Uni-
versity of Lausanne approved the CoLaus|PsyCoLaus
study. All participants signed a written informed consent
after having received a detailed description of the goal and
funding of the study.
Body weight, height, waist and hip circumferences were
measured at the out-patient clinic at the Centre Hospi-
talier Universitaire Vaudois (CHUV)37.
Genotyping, quality control, and imputation are
described in Supplementary Methods 1.1.
NESDA|NTR
NESDA|NTR included 4821 unrelated participants of
North-European ancestry from the Netherlands Study of
Depression and Anxiety (NESDA, n= 2047) and from the
Netherlands Twin Register (NTR, n= 2774). Detailed
descriptions of the rationale, design, and methods for both
studies are given elsewhere21,39. Briefly, NESDA is an
ongoing cohort study on the long-term course and con-
sequences of depressive and anxiety disorders. In
2004–2007, 2981 participants with depression and anxiety
disorders and healthy controls aged 18–65 years were
recruited from the community (19%), general practice
(54%), and secondary mental health care (27%) and were
followed-up during five biannual assessments. The NTR
study has been collecting longitudinal data on Dutch adult
twin families since 1991 (ref. 40). The research protocols
from both studies were approved by the Central Ethics
Committee on Research Involving Human Subjects of the
VU University Medical Center, Amsterdam, an Institu-
tional Review Board certified by the U.S. Office of Human
Research Protections (IRB number IRB00002991 under
Federal-wide Assurance FWA00017598; IRB/institute
codes) and informed consent was obtained from all par-
ticipants. People with MDD were derived from NESDA.
Lifetime MDD diagnoses according to the DSM-IV and
specific atypical symptoms were ascertained using the
Composite Interview Diagnostic Instrument, which at the
9-year follow-up was extended with additional questions
in order to elicit all atypical symptoms41. Healthy controls
were screened based on the absence of any lifetime psy-
chiatric disorder (NESDA). NTR controls were selected
based on no report of MDD, no known first-degree
relatives with MDD, and a low factor score based on a
multivariate analysis of depressive complaints, anxiety,
neuroticism, and somatic anxiety42.
Body weight, height, waist and hip circumferences were
measured by medical examination at the study clinic
during the visit for NESDA21 and during the home visit
after blood sampling for NTR43.
Genotyping, quality control, and imputation are
described in Supplementary Methods 1.2.
Statistical analyses
We tested BMI and WHR as measures of obesity
(exposures) and used two-sample MR44,45 to test whether
they are causal risk factors for six different outcomes. One
outcome was based on the MDD atypical subtype defi-
nition: (1) atypicals vs controls, and (2–6) the presence or
absence of each of the five atypical subtype symptoms.
MR infers causality by using genetic variants (as instru-
mental variables) reliably associated with an exposure and
regressing their effect on the exposure against their effect
on the outcome. Summary statistics for BMI46 and
WHR47 were obtained from large GWAS of international
consortia and genome-wide significant independent SNPs
were selected as instruments (Supplementary Methods
2.1). An important assumption of MR is that each SNP
must only influence the risk of the outcome through the
exposure under investigation, as the inclusion of SNPs
that contribute through a pleiotropic pathway could bias
estimates48. To assess for the presence of directional
horizontal pleiotropy, we used MR-Egger regression49.
We performed inverse variance weighted (IVW) instru-
mental variable analysis followed by sensitivity analyses
based on weighted-median and simple-median causal
estimators, which provide consistent causal estimates
even when up to half of instruments are violating MR
assumptions. Analyses were conducted using the Two-
SampleMR R package44,45 (Supplementary Methods 2.2).
Since population stratification is another potential source
of bias for MR analyses, we selected summary statistics
from GWAS that included only individuals of European
descent for both BMI and WHR. CoLaus|PsyCoLaus and
NESDA|NTR were two cohorts which contributed to
both the BMI and WHR meta-analyses, together provid-
ing respectively 8924 and 8914 individuals overall and
accounting for 1.31% and 1.28% of the two meta-analysis
sample sizes. There are two kinds of biases present in the
two-sample MR context: overlapping samples lead to bias
toward the observational correlation50,51, while winner’s
course biases the causal effect estimate toward zero. Both
biases are mitigated by the use of strong instruments. This
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was confirmed in CoLaus|PsyCoLaus given that the
instrumental variables for BMI and WHR revealed strong
associations with their respective phenotypes (F= 30.74
for BMI and F= 13.45 for WHR). Usually F > 10.0 is
required for an adequate instrumental variable26. The two
instrumental variables explained 5.5% and 2.4% of the
phenotypic variance, respectively. For each outcome, we
conducted a case-control GWAS separately on CoLaus|
PsyCoLaus and NESDA|NTR and then we ran fixed
effects meta-analyses of the results of the two cohorts
using the IVW method implemented in METAL52 (Sup-
plementary Tables 1–14). Logistic regression models were
adjusted for year of birth, gender, and the first five
ancestry-informative genetic principal components.
Models on symptoms were also additionally adjusted for
the other four symptoms. For the analyses involving the
five atypical symptoms, the significance level was set to p
= 0.01 (0.05/5) according to the Bonferroni correction for
multiple testing. In NESDA|NTR, these analyses were
based on the whole sample with the coding of depressive
symptoms as absent in controls, whereas in CoLaus|Psy-
CoLaus the respective analyses were restricted to parti-
cipants who entered the depression section.
Results
MDD atypical subtype and atypical symptoms in the two
cohorts
Table 1 provides the description of the 2643 partici-
pants with lifetime MDD and the 4846 controls of the two
cohorts. Among the participants with MDD, 565 met
criteria for atypical MDD according to the DSM-IV. As
expected, the age of onset of MDD was lower and the
number of episodes was higher in the clinical NESDA|
NTR study as compared to the population-based CoLaus|
PsyColaus study.
The table also shows the distribution of depressive
symptoms in the two cohorts. In CoLaus|PsyCoLaus, the
presence of depressive symptoms was assessed in the 1958
participants (i.e. 58.4% of the entire sample) who had
entered the depression section (regardless of whether they
fulfilled criteria for MDD or not), whereas in NESDA|
NTR information on symptoms was only available for
participants meeting criteria for MDD (symptoms were
recorded as absent for controls).
MR analyses
Table 2 and Fig. 1 provide the results from two-sample
MR analyses. The analysis testing the effect of BMI on
atypical MDD did not reveal evidence for a causal role in
the meta-analysis as well as in the two studies. As
expected, we did not find evidence for a causal effect of
BMI on non-atypical MDD either. Analyses focusing on
the atypical symptoms consistently supported an asso-
ciation between the instrumental variable for BMI and the
symptom increase in appetite according to all three
approaches (IVW p= 0.004, simple median p= 0.036,
and weighted median p= 0.004). The IVW and weighted
median MR regression estimates remained significant
after Bonferroni correction. In contrast, there was no
evidence for a causal association between the BMI and
atypical symptoms other than increase of appetite. Com-
parison of the results according to the IVW method in the
two studies reveals that the association between BMI and
increase in appetite was stronger in CoLaus|PsyCoLaus
than in NESDA|NTR. For the other symptoms, CoLaus|
PsyCoLaus revealed no associations according to the IVW
method, whereas NESDA|NTR even showed significantly
negative associations between BMI and mood reactivity as
well as rejection sensitivity.
Secondary analyses tested the potential causal role of
obesity on atypical MDD and its symptoms using WHR as
a measure of obesity. This measure did not provide evi-
dence for a causal role of obesity on atypical MDD either.
Analyses focusing on the atypical symptoms provided MR
estimates that were directionally consistent with those
based on BMI. However, the associations between the
instrumental variable and the symptom increase in
appetite failed to reach the level of significance after
Bonferroni correction. Comparison of the results
according to the IVW method between the two studies
showed a significant association between WHR and
increase in appetite in NESDA|NTR but not in CoLaus|
PsyCoLaus. Table 3 reveals that the Egger method did not
provide evidence for any pleiotropy.
Discussion
The present paper is, to our knowledge, the first to
investigate the causal relationship between obesity and the
MDD atypical subtype and its specific symptoms
according to the DSM specifier using a MR approach. We
tested BMI and WHR as measures of obesity. Our ana-
lyses supported a causal link between BMI and the aty-
pical symptom increase in appetite but not atypical MDD
as a whole. In contrast, we did not find evidence of a
causal effect of BMI on the other atypical symptoms. The
differential results across the five symptoms of atypical
MDD suggest genetic heterogeneity, which also accounts
for the observed absence of an association between BMI
and atypical MDD. Our result, suggesting a causal link
between BMI and increase in appetite, is compatible with
those from a recent MR study by Kappelmann et al.36,
which found that higher BMI could be causally related to
the symptom change in appetite. However, the authors
could not differentiate between the underlying diame-
trically opposite symptoms of increase and decrease in
appetite. In contrast to BMI, the association between
WHR and an increase in appetite shortly failed to reach
the level of statistical significance according to the IVW
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method in our study, although the effect size for this
association was even higher than that established for the
association between BMI and increase in appetite (β=
0.78 vs β= 0.68, respectively). This apparently paradoxical
result is likely to be attributable to the weaker instru-
mental variable for WHR, which was based on a smaller
number SNPs entailing a larger standard error and a
weaker association with its phenotype.
Although our results supported a causal relationship
between BMI and increase in appetite during depression,
which is one of five criteria for atypical depression
according to the DSM-IV, we did not find evidence for a
causal relationship between BMI and atypical depression as
a whole. The latter finding can be explained by the absence
of evidence for causal associations between BMI and all
atypical symptoms other than increase in appetite, whereas
increase in appetite is not even a mandatory criterion for
atypical depression. Hence, the BMI is likely to be more
strongly causally associated with a depression subtype that
is solely characterized by a mandatory increase in appetite
rather than with atypical depression according to the DSM-
IV definition. The causal effect of BMI over the symptom
increase in appetite during depression may find an expla-
nation in the alteration of inflammatory, metabolic, and
bioenergetics biological pathways resulting in hyperphagia,
which is central for obesity and can also occur during
depressive episodes. This hypothesis would be compatible
with results of a previous study demonstrating positive
associations between the polygenic risk scores for BMI,
leptin, and C-reactive protein and a major depression
subtype characterized by increase in appetite or weight9. In
contrast, according to our results, the frequently observed
association between BMI and atypical depression11–17
cannot be explained by a relationship with BMI causing this
depression subtype. An inverse causal relationship or
shared genetic liability could account for the phenotypic
association between BMI and atypical depression. Indeed,
prospective data revealed that atypical depression is a risk
factor for a subsequent increase in obesity markers11,15.
Unfortunately, we lack a polygenic risk score for atypical
depression, which would allow us to test causality using the
MR approach. Previous results of the NESDA study have
also supported shared genetic liability between BMI and
atypical depression. Indeed, a polymorphism of the FTO
Table 1 Demographic and clinical characteristics and distribution of atypical symptoms in CoLaus|PsyCoLaus and
NESDA|NTR.
CoLaus|PsyCoLaus NESDA | NTR
MDD Atypical MDD No MDD Participants
endorsing atypical
symptoms
MDD Atypical MDD No MDD Participants
endorsing atypical
symptoms
Total N 1461 386 1889 1958 1182 179 2957 4139
Female (%) 66.12 72.54 43.41 63.02 68.52 70.39 60.97 63.13
Mean year of
birth (SD)
1955 (8.5) 1955 (8.3) 1954 (8.7) 1955 (8.5) 1962 (12.5) 1963 (12.1) 1963 (15.7) 1963 (14.9)
Number of episodes (%):
1 episode 59.07 48.70 – – 1.70 1.60 – –
2 episodes 22.38 25.91 – – 22.60 16.10 – –
>2 episodes 18.48 25.39 – – 75.70 82.30 – –
Mean age of
onset (SD)
33.81 (12.9) 33.10 (13.4) – – 27.8 (12.9) 24.3 (12.4) – –
Increase in
appetite (%)
17.18 40.67 – 14.15 8.79 37.43 – 2.51
Hypersomnia (%) 24.84 48.70 – 20.38 15.31 56.98 – 4.37
Mood reactivity (%) 69.95 100.00 – 72.37 32.82 100.00 – 9.37
Leaden
paralysis (%)
29.77 59.06 – 24.41 23.60 81.56 – 6.74
Rejection
sensitivity (%)
66.11 90.15 – 61.08 19.96 75.42 – 5.70
Number of episodes available in 59% of NESDA|NTR MDD cases and 69% of NESDA|NTR atypical MDD cases.
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Table 2 Results of the Mendelian Randomization analyses in CoLaus|PsyCoLaus, NESDA|NTR, and in their combined
dataset.
Dataset Exposures Outcomes N SNPs Inverse variance
weighted
Simple median Weighted median
Beta SE p Beta SE p Beta SE p
CoLaus|PsyCoLaus+
NESDA|NTR combined
BMI Atypical MDD vs
controls
594 −0.14 0.19 0.471 −0.14 0.29 0.632 −0.06 0.30 0.843
Non-atypical MDD vs
controls
593 0.04 0.12 0.731 −0.03 0.18 0.882 −0.07 0.19 0.725
Increase in appetite 593 0.68 0.23 0.004* 0.77 0.37 0.036 1.11 0.39 0.004*
Hypersomnia 593 0.05 0.20 0.812 0.16 0.29 0.584 0.36 0.34 0.298
Mood reactivity 593 −0.23 0.16 0.132 −0.36 0.24 0.130 −0.04 0.24 0.881
Leaden paralysis 593 −0.11 0.17 0.518 −0.21 0.27 0.436 −0.46 0.28 0.096
Rejection sensitivity 593 −0.23 0.16 0.152 −0.30 0.26 0.248 0.14 0.29 0.643
WHR Atypical MDD vs
controls
330 0.33 0.25 0.199 −0.09 0.40 0.822 −0.06 0.39 0.877
Non-atypical MDD vs
controls
329 −0.11 0.16 0.482 0.09 0.23 0.691 −0.03 0.24 0.900
Increase in appetite 330 0.78 0.31 0.011 0.87 0.44 0.050 0.91 0.52 0.078
Hypersomnia 331 0.46 0.27 0.092 0.64 0.39 0.099 0.32 0.43 0.459
Mood reactivity 331 0.40 0.22 0.068 0.44 0.30 0.152 0.44 0.32 0.172
Leaden paralysis 331 0.08 0.22 0.724 0.38 0.34 0.261 0.41 0.34 0.223
Rejection sensitivity 330 −0.13 0.23 0.568 −0.46 0.31 0.140 −0.09 0.35 0.787
CoLaus|PsyCoLaus BMI Atypical MDD vs
controls
593 0.24 0.24 0.319 0.30 0.36 0.396 0.26 0.40 0.526
Non-atypical MDD vs
controls
593 −0.13 0.17 0.447 0.13 0.26 0.605 0.19 0.30 0.537
Increase in appetite 592 0.82 0.28 0.004* 0.55 0.44 0.206 0.75 0.47 0.113
Hypersomnia 592 0.35 0.25 0.153 0.19 0.38 0.621 0.47 0.42 0.267
Mood reactivity 592 0.16 0.21 0.442 0.01 0.33 0.980 0.74 0.35 0.036
Leaden paralysis 592 0.26 0.24 0.286 −0.02 0.37 0.957 −0.18 0.36 0.607
Rejection sensitivity 591 0.08 0.20 0.677 −0.05 0.31 0.879 0.02 0.34 0.943
WHR Atypical MDD vs
controls
330 0.05 0.32 0.879 0.13 0.47 0.781 0.20 0.49 0.678
Non-atypical MDD vs
controls
330 −0.20 0.22 0.352 −0.04 0.35 0.911 −0.14 0.34 0.688
Increase in appetite 330 0.56 0.40 0.154 0.35 0.56 0.529 0.36 0.58 0.541
Hypersomnia 330 0.23 0.33 0.487 0.70 0.50 0.164 −0.15 0.50 0.766
Mood reactivity 330 0.05 0.30 0.861 −0.01 0.43 0.974 −0.11 0.46 0.809
Leaden paralysis 330 −0.03 0.31 0.935 −0.25 0.45 0.585 −0.43 0.47 0.368
Rejection sensitivity 330 −0.30 0.27 0.268 −0.62 0.39 0.109 −0.54 0.42 0.194
NESDA|NTR BMI Atypical MDD vs
controls
592 −0.80 0.32 0.013 −1.03 0.48 0.031 −0.15 0.52 0.771
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Table 2 continued
Dataset Exposures Outcomes N SNPs Inverse variance
weighted
Simple median Weighted median
Beta SE p Beta SE p Beta SE p
Non-atypical MDD vs
controls
592 0.19 0.16 0.236 0.23 0.23 0.315 0.38 0.26 0.140
Increase in appetite 592 0.36 0.42 0.392 0.14 0.62 0.825 0.14 0.73 0.846
Hypersomnia 592 −0.49 0.32 0.131 −0.45 0.50 0.376 −0.18 0.56 0.742
Mood reactivity 591 −0.66 0.22 0.003* −0.54 0.33 0.103 −0.50 0.37 0.169
Leaden paralysis 592 −0.57 0.26 0.027 −0.25 0.40 0.541 −0.51 0.44 0.249
Rejection sensitivity 592 −0.91 0.28 0.001* −0.97 0.43 0.022 −1.11 0.49 0.023
WHR Atypical MDD vs
controls
330 0.81 0.43 0.061 0.22 0.65 0.732 0.84 0.65 0.197
Non-atypical MDD vs
controls
330 0.01 0.22 0.977 0.10 0.31 0.742 −0.09 0.34 0.801
Increase in appetite 330 1.37 0.53 0.009* 1.07 0.79 0.172 1.53 0.83 0.066
Hypersomnia 330 0.82 0.43 0.055 1.45 0.63 0.021 1.47 0.68 0.029
Mood reactivity 330 0.77 0.32 0.017 0.76 0.45 0.094 0.79 0.48 0.100
Leaden paralysis 330 0.23 0.35 0.508 −0.15 0.53 0.771 0.01 0.56 0.988
Rejection sensitivity 329 0.06 0.37 0.877 −0.13 0.56 0.817 0.09 0.60 0.878
Nominal significant associations are in bold and associations on symptoms surviving correction for multiple testing alpha level of 0.01 (0.05/5) are denoted with an
asterisk.
BMI body mass index, WHR waist-to-hip ratio.
Fig. 1 Test of whether BMI and WHR adiposity measures are causal risk factors for increase in appetite. The panels plot per-allele effect sizes
for a BMI, b WHR (x-axes) against per-allele effect size for increase in appetite (y-axis). For adiposity measures, effect sizes are measured in SDs, for
increase in appetite symptom the effect size is log-odds ratio. For each plot, we estimated the slope using inverse-variance weighted regression (light
blue line), simple-median regression (light green line), weighted-median regression (dark green line), and Egger regression (dark blue line).
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Table 3 Results of the Mendelian Randomization analyses using the MR-Egger method in CoLaus|PsyCoLaus, NESDA|
NTR, and in their combined dataset.
Dataset Exposures Outcomes N SNPs MR-Egger
Intercept Slope
Beta SE p Beta SE p
CoLaus|PsyCoLaus+NESDA|NTR combined BMI Atypical MDD vs controls 594 0.002 0.009 0.850 −0.236 0.547 0.666
Non atypical MDD vs controls 593 −9E−05 0.005 0.987 0.045 0.329 0.891
Increase in appetite 593 −0.003 0.011 0.778 0.855 0.660 0.196
Hypersomnia 593 −0.008 0.009 0.398 0.493 0.563 0.382
Mood reactivity 593 −0.013 0.007 0.064 0.527 0.439 0.231
Leaden paralysis 593 0.011 0.008 0.169 −0.732 0.482 0.130
Rejection sensitivity 593 −0.004 0.007 0.545 0.028 0.459 0.952
WHR Atypical MDD vs controls 330 −0.019 0.012 0.117 1.388 0.721 0.055
Non atypical MDD vs controls 329 0.008 0.008 0.275 −0.586 0.462 0.206
Increase in appetite 330 −0.027 0.015 0.067 2.309 0.885 0.009*
Hypersomnia 331 0.004 0.013 0.750 0.223 0.779 0.775
Mood reactivity 331 −0.007 0.010 0.521 0.778 0.627 0.216
Leaden paralysis 331 0.013 0.011 0.218 −0.664 0.641 0.301
Rejection sensitivity 330 −0.009 0.011 0.395 0.391 0.651 0.548
CoLaus|PsyCoLaus BMI Atypical MDD vs controls 593 0.004 0.011 0.692 −0.012 0.690 0.986
Non atypical MDD vs controls 593 0.009 0.008 0.218 −0.684 0.481 0.155
Increase in appetite 592 0.003 0.013 0.831 0.660 0.793 0.405
Hypersomnia 592 −0.011 0.011 0.330 0.985 0.694 0.156
Mood reactivity 592 −0.022 0.010 0.024 1.448 0.605 0.017
Leaden paralysis 592 0.009 0.011 0.406 −0.274 0.687 0.690
Rejection sensitivity 591 −0.004 0.009 0.651 0.319 0.559 0.568
WHR Atypical MDD vs controls 330 −0.017 0.016 0.277 1.012 0.940 0.283
Non atypical MDD vs controls 330 0.017 0.011 0.117 −1.161 0.648 0.074
Increase in appetite 330 −0.035 0.020 0.081 2.540 1.195 0.034
Hypersomnia 330 0.018 0.016 0.283 −0.769 0.986 0.436
Mood reactivity 330 −0.008 0.015 0.575 0.520 0.886 0.558
Leaden paralysis 330 0.019 0.015 0.203 −1.126 0.917 0.220
Rejection sensitivity 330 −0.014 0.013 0.296 0.485 0.793 0.541
NESDA|NTR BMI Atypical MDD vs controls 592 −0.004 0.015 0.808 −0.597 0.914 0.514
Non atypical MDD vs controls 592 −0.008 0.007 0.256 0.656 0.443 0.139
Increase in appetite 592 −0.018 0.019 0.349 1.402 1.187 0.238
Hypersomnia 592 −0.002 0.015 0.886 −0.365 0.915 0.690
Mood reactivity 591 −0.005 0.010 0.638 −0.384 0.623 0.538
Leaden paralysis 592 0.013 0.012 0.275 −1.310 0.727 0.072
Rejection sensitivity 592 −0.005 0.013 0.691 −0.620 0.786 0.431
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gene, which has been shown to be consistently associated
with obesity and body mass regulation in Europeans53–56,
was also found to be positively associated with atypical
depression57.
Limitations
The results of the present study need to be viewed in the
light of several limitations. First, the two cohorts relied on
partially different methodologies regarding the sampling
of cases and controls as well as the instruments used for
diagnostic assessment. The differential methodology is
likely to account for heterogeneity between the two
samples, which is reflected by differential depression
severity and distributions of atypical symptoms. Second,
we could not test for a potential bidirectional causal
relationship between atypical MDD or its symptoms and
BMI or WHR, because large and sufficiently powered
GWAS meta-analyses performed on the atypical depres-
sion subtype or atypical symptoms are still lacking.
Therefore, at this stage there are no instrumental variables
available for atypical MDD or atypical depression symp-
toms which would allow us to test for causal effects of
atypical MDD or atypical symptoms on BMI or WHR
according to the two-sample MR approach. Moreover, a
one-sample MR analysis could not be conducted in the
CoLaus|PsyCoLaus and NESDA|NTR cohorts given an
insufficient sample size. This may be done in the future
when robust GWAS on atypical depression and on its
symptoms will become available.
Third, limited statistical power due to limited sample
size in the two studies could account for negative findings.
Indeed, beside the association between WHR and increase
in appetite, which shortly failed to reach the level of sta-
tistical significance, also the associations between WHR
and both hypersomnia and mood reactivity may have
reached statistical significance in larger samples according
to the IVW method.
Conclusions
In the last years, the heterogeneity of depression has
been partially disentangled by the characterization of its
subtypes which represented a promising strategy to gain
additional insight into its complex pathophysiology and
relationship with obesity. Recent evidence converges in
indicating that immuno-metabolic biological dysregula-
tions map more consistently to atypical symptom profiles
characterized by alterations in energy homeostasis
(increase in appetite, hypersomnia, leaden paralysis, fati-
gue)22. Building on this evidence, the existence of an
“immune-metabolic depression” (IMD) dimension emer-
ging from the clustering of energy-related clinical symp-
toms with inflammatory and metabolic dysregulations has
been postulated. Findings from the present study partially
support this hypothesis, showing that the liability for
higher BMI is potentially causally related with the devel-
opment of the specific symptom of increase in appetite in
depressed participants. Further experimental and func-
tional studies will be needed to fully elucidate the
mechanistic chains underlying this causal association.
Overall, results from our analyses reiterate the need to
study depression at the granular level of its individual
symptoms to further elucidate potential causal relation-
ships and gain additional insight into the biological
mechanisms of depression.
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